Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Key Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of NSCLC with EGFR mutations known to be associated with EGFR TKI sensitivity, EGFR T790M negative and MET gene amplification
* Stage IIIB/IIIC or IV NSCLC
* Participants must have progressed on one prior line of therapy (1st/2nd generation EGFR TKIs, osimertinib or other third generation EGFR TKIs) for advanced/metastatic disease (stage IIIB/IIIC and must be candidates for platinum (cisplatin or carboplatin) - pemetrexed doublet based chemotherapy
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
* Participants must have recovered from all toxicities related to prior systemic therapy to grade ≤ 1 Common Terminology Criteria Adverse Event 5.0 (CTCAE v 5.0)
* At least one measurable lesion as defined by RECIST 1.1
* Participants must have adequate organ function

Key Exclusion Criteria:

* Prior treatment with any MET inhibitor or HGF-targeting therapy
* Participants with symptomatic central nervous system (CNS) metastases who were neurologically unstable or had required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms
* Carcinomatous meningitis
* Presence or history of a malignant disease other than NSCLC that had been diagnosed and/or required therapy within the past 3 years
* Presence or history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis
* Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome
* Clinically significant, uncontrolled heart diseases
* known druggable molecular alterations that may render participants eligible for alternative targeted therapies